Johnson & Johnson has been dedicated to developing innovative treatments for blood cancers for nearly 20 years. Scientist Kodandaram “Ram” Pillarisetti is at the forefront of the company’s commitment to working toward its goal of one day eliminating the disease.

When Craig was diagnosed with multiple myeloma, his wife Cara took on a new role: caregiver. Here, she shares the challenges—as well as the triumphs—of this difficult journey.

For World Health Day, learn how Johnson & Johnson’s commitment to Diversity, Equity and Inclusion is helping to deliver transformational cancer treatments and solutions that reach the patients who need them most.

A commitment to social responsibility and innovation are just two of the attributes that helped the company land a spot on the prestigious list once again.

Mobilizing to help coworkers in need. Increasing diverse representation in clinical trials. Advocating on behalf of people living with life-altering medical conditions. Learn about the extraordinary ways these trailblazers made a difference in 2022.

Rates of this blood cancer have jumped more than 125% worldwide since the 1990s. But there’s reason to have hope: Today, life expectancy has at least doubled in some cases. That’s thanks to increased research, new learnings and innovative advances—and Johnson & Johnson is at the forefront of this crucial work.

For National Cancer Prevention Month, we’re spotlighting three leading Johnson & Johnson female hematologists—innovators who are not only saving lives and advancing new treatments but also paving the way for the next generation of women in their field.

What do diseases like multiple myeloma and lupus have in common? They’re more prevalent in people of color—yet historically these patients have been left out of clinical research, often to dire health consequences. Learn how Johnson & Johnson is working to make the study of conditions like these more equitable.

Imagine having a disease that many doctors have never seen before. That’s what Marty Verel experienced when he was told he had AL amyloidosis—and it’s what hematologist Brendan Weiss, M.D., is determined to help change. For Rare Disease Day, Dr. Weiss shares what he’s learned studying the rare disease.

Brad Heidrich’s diagnosis with a deadly cancer at age 13 changed the course of his life—and inspired the person he would become: a Janssen scientist dedicated to working on therapies for blood cancer. For National Cancer Survivor Month, we share his incredible story.